PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
|
|
- Virgil Johnson
- 5 years ago
- Views:
Transcription
1 PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final
2 1. T.P., a 66-year-old, 72 kg male (SrCr 1.6mg/dL), has been taking 0.25mg of digoxin tablets orally for his CHF, and at 9.00am on the day of admission, a digoxin plasma concentration of 1.1µg/L was measured. He was continued on his outpatient maintenance dose. On the third day, just before his morning dose (two doses of digoxin have been administered each day at 9.00am), a second digoxin sample was obtained. Using the expected pharmacokinetic parameters, calculate L.P. s digoxin concentration on the morning of the third day. (8 pts.) A. 0.6 µg/l B. 1.0 µg/l C. 1.3 µg/l D. 1.6 µg/l E. 1.9 µg/l Key : C ( ) 72 CL Cr 46.25mL / min CL mL / min 3.9L / h 93.6L / day Vd L 417L k e CL Vd days 1 C min( sum ) 1.1 e C measured days e k e t F D + Vd k t [ e e t 1 k + e e 2 ] days days [ e + e ] µg / L [ ] Final
3 2. S. J., a 70 kg female patient was given 60 mg gentamicin over 30 minutes (i.v.) from 8:30 to 9:00 am. The following two serum levels were measured: 6.5 µg/ml at 9:30 am and 1.2 µg/ml at 4:00 pm. Calculate his peak concentration at 9:00 am. (6 pts.) A. 7.0 μg/ml B. 7.4 μg/ml C. 7.8 μg/ml D. 8.2 μg/ml E. 8.6 μg/ml Key: B The elimination rate constant k is k 6.5 ln h 1 The peak concentration at 9:00 am is C max e μg / ml Final
4 3. M.F., a 28-year-old, 75 kg male, is receiving 100 mg of tobramycin infused IV over 30 minute period q8h. His serum creatinine has increased from 1 mg/dl to 1.8 mg/dl over the past 24 hours. Since his renal function appears to be decreasing, three plasma samples were obtained to monitor serum gentamicin concentrations as follows: just before a dose; one hour after the start of that same dose; and eight hours after the start of that dose (two troughs and one peak level). The serum tobramycin concentrations at these times were 4 mg/l, 8 mg/l, and 5 mg/l, respectively. Calculate the volume of distribution of tobramycin for M.F using the following equation. (6 pts.) Vd 100 k 0.5 k 0.5 ( 1 e ) k 0.5 ( C C e ) max min What should be the values for k (h -1 ), Cmax (mg/l) and Cmin (mg/l) in the above equation? A , 8.3, 5 B , 8, 5 C , 8.3, 4 D , 8, 4 E , 8, 5 Key: C 8 ln k 0.067h max C e 8 mg/l Cmin should be the pre-dose concentration 4 mg/l. Final
5 4. Show how an increase in tissue binding will affect the clearance, bioavailability and halflife of a high-extraction drug. (6 pts.) A. Clearance is decreased, bioavailability is not changed, Half-life is increased B. Clearance is decreased, bioavailability is not changed, Half-life is not changed C. Clearance is not changed, bioavailability is not changed, Half-life is not changed D. Clearance is not changed, bioavailability is not changed, Half-life is increased E. Clearance is decreased, bioavailability is increased, Half-life is increased Key: D Vd fu VB + VT fu T Clearance and bioavailability are not changed Half-life is increased due to increase in Vd Final
6 5. V.W., a 15-year-old, 32 kg male, is receiving 250 mg of valproic acid q12h for absence seizures. His steady-state trough concentration was 30 mg/l. Because of inadequate seizure control and the lack of apparent side effects, it is decided to increase the trough concentration to 55 mg/l. What dose will be required to achieve the target trough concentration of 55mg/L if the dosing interval is decreased from q12h to q8h? (8 pts.) A. 120 mg q8h B. 250 mg q8h C. 125 mg q8h D. 80 mg q8h E. 400 mg q8h Key: B Vd 0.14L / kg weight 0.14L / kg 32kg 4. 48L Dose F S 250mg 1 1 C max Cmin + 30mg / L mg / L Vd 4.48L Cp1 85.8mg / L ln ln Cp2 30mg / L 1 k e 0.088h t 12h ke τ Cpss Vd e mg L L e 124.5mg Dose,min 1 55 / ke τ F S e 1 1 e mg q8h ( ) ( ) mg mg Final
7 6. S.V., a 34 y.o. female patient (54 kg, SeCr 1.1 mg/dl) received a 30 mg methotrexate loading dose iv followed by a 30 mg/h infusion over 36 hours. Her levels at 24h and 48h were 12.2 µm and 0.76 µm, respectively. Calculate the anticipated methotrexate level at 60 hours. (8 pts.) A. 0.5 µm B µm C. 0.1 µm D µm E. 0.4 µm Key: D Cp ln Cp t µM ln 0.76 µm h 2 1 k e h t 1 3h 2 t at 0.5 µm: Cp1 12.2µM ln ln Cp 2 0.5µM t 1 k 0.231h e 13.8h t 3h t h h 13.8h 36h 10. 2h ( 60h) 0.5µM e 0. µm Cp 25 k e h t 10h 1 2 Final
8 7. T.K. is a 25 year old 75 kg chronic asthmatic who is hospitalized with severe asthma. She is treated there with aerosol albuterol, but has a poor response. She is then given 350 mg of IV aminophylline over 30 minutes. Thirty minutes after the loading dose was administered (60 minutes from time zero) the theophylline concentration was 10 μg/ml. She has normal liver, kidney, and cardiac function and is afebrile. After the loading dose, T.K. was started on an IV aminophylline of 60mg/h and albuterol nebulization. Eight hours after the first serum level, a second level was 16 μg/ml. Using T.K.'s actual volume of distribution, calculate her expected steady state theophylline concentration for the infusion rate of 40mg/h aminophylline. (8 pts.) A. 10 μg/ml B. 15 μg/ml C. 20 μg/ml D. 25 μg/ml E. 30 μg/ml Key: B Vd D * S C * L (10 16 ) CL ( ) ( ) L / h C μg / ml Final
9 8. A patient (male, 35y, 74 kg) with a subtherapeutic theophylline (3 μg/ml) is admitted to the ICU. Based on average pharmacokinetics parameters (Vd 0.5 L/kg, t 1/2 8 h)), calculated an i.v. bolus loading dose and a maintenance dose (i.v. infusion) to increase the level to 15 μg/ml. (6 pts.) A. 350mg, 50mg/h B. 450mg, 40mg/h C. 450mg, 50mg/h D. 550mg, 40mg/h E. 550mg, 50mg/h Key: C V d L LD (15 3 ) mg CL 37 8 MD mg/h 3.21L / h Final
10 9. Z. T., a 62-year old, 60-kg woman with a serum creatinine of 1 mg/dl, has been started on 500 mg of vancomycin every 8 hours for the treatment of staphylococcal infection. What is the expected trough vancomycin concentrations for her at steady state? (6 pts.) A. 20 mg/l B. 13 mg/dl C. 13 mg/l D. 26 mg/dl E. 26 mg/l Key: C Vd 0.17(62)+0.22(60) L CL Cl cr 0.85 ( )(60 ) ml/min 3.32 L/h 72 1 Ke CL/Vd 3.32/ h -1 S F Dose (1)(1)( 500 ) Vd ( ) Css max k τ e 1 e 26mg / L k τ Css min Css max e 26.0 e 13mg / L Final
11 Key : B 10. Inhibition of P-glycoprotein will result in A. lower cyclosporin bioavailability and lower digoxin levels in the brain B. higher cyclosporin bioavailability and higher digoxin levels in the brain C. higher cyclosporin bioavailability and unchanged digoxin levels in the brain D. unchanged cyclosporin bioavailability and lower digoxin levels in the brain E. lower cyclosporin bioavailability and higher digoxin levels in the brain (6 pts.) Final
12 11. Which of the following statements about the pharmacokinetics (PK) and pharmacodynamics (PD) of midazolam in elderly patients is correct? (6 pts.) A. PK and PD are the same as in young patients B. PK is the same as in young patients, but PD is different C. PD is the same as in young patients, but PK is different D. PK and PD are different in comparison to young patients E. PD is different compared to young patients due to changes in PK Key : B Final
13 12. Which of the following changes goes along with an increased clearance and no change in volume of distribution? (6 pts.) A. increased initial concentration after an i.v. bolus, longer time to steady state B. shorter half-life, higher steady state concentration C. longer time to steady state, shorter half life D. shorter time to steady state, lower steady state concentration E. shorter time to steady state, higher steady state concentration Key : D Final
14 13. A 50 year-old female (5 4, 125 lbs) is admitted to the emergency room with ventricular tachycardia and chest pain consistent with an evolving mycardial infarction. She is given a bolus of lidocaine and started immediately on a lidocaine infusion of 2 mg/min. Routine laboratory analyses reveal a serum creatinine and BUN of 3.0 and 48 mg/100 ml, respectively. Although lidocaine eliminates ventricular tachycardia, frequent hemodynamically significant ventricular ectopy is still present 12 hours later. Procainamide is given first as a loading dose of 17 mg/kg over one hour and then followed by a maintenance infusion of 120 mg/hour. Serum concentrations of procainamide and NAPA at the end of the loading infusion are 7 and 4 mg/l, respectively. Serum concentrations of procainamide one, six, and 24 hours following initiation of maintenance infusion are 7, 8 and 9 mg/l, respectively. Corresponding values for NAPA are 4, 9, and 14 mg/l, respectively. Ventricular ectopy is completely abolished beginning about 30 minutes after the loading infusion was administered and no further arrhythmias are noted. The physician now wants to dose procainamide orally. Make appropriate dose recommendations for use of oral procainamide in this atient. You must show all calculations and clearly state all assumptions. (8 pts.) A mg B. 870 mg C. 550 mg D. 480 mg E. 200 mg Key: C or B weight / kg 125lbs kg CL R 0 F S Cp ss 120mg / h L / h 9mg / L LD F S 17mg / kg 56.75kg Vd L Cp 7mg / L Vd L t h 7h 2 CL 11.33L / h k e t h 7h Final
15 the dosing interval should be equal or less than the half-life Cp1 8mg / L ln Cp ln 2 4mg / L τ 7h τ 6h ke Cpss CL τ 6mg / L 11.33L / h 6h mg Dose mg 550mg F S C if you chose a dosing interval of τ 8h : Cpss CL τ 6mg / L 11.33L / h 8h mg Dose mg 870mg F S B Final
16 14. M.W. is a 33-year-old, 65 kg male with a seizure disorder that has only partially been controlled with 300 mg/day of sodium phenytoin. His plasma phenytoin concentration has been measured twice over the past year and both times it was reported to be 7 mg/l. His Km value is 5 mg/l. Calculate a dose which will achieve a steady-state concentration of 15 mg/l. (6 pts.) A. 800 mg B. 400 mg C. 200 mg D. 250 mg E. 600 mg Key: B Vm F S Dose / τ Cp ( Km + Cpss, ave ) mg / day ( 5mg / L + 7mg / L) ss, ave 7mg / L mg / day 7 Dose Vm Cp ss, ave 473mg / day 15mg / L 1day ( Km + Cp ) F S ( 5mg / L + 15mg / L) ss, ave τ mg 400mg 18.4 Final
17 15. N.S., a 36-year-old, 60 kg female, is to be given carbamazepine orally as an anticonvulsant agent. Calculate a daily dose that will produce an average steady-state plasma concentration of approximately 6 mg/l. (6 pts.) A. 30 mg B. 350 mg C. 700 mg D mg E. 45 mg Key: C CL 0.064L / kg / h weight 0.064L / kg / h 60kg 3.84L / h Cp Dose ss, ave CL τ 6mg / L 3.84L / h 24h F S mg 700mg Final
18 16. E.S., an 8-year-old, 25 kg male, is being treated for a seizure disorder. She has been receiving 100 mg/day of phenobarbital (50 mg BID) for the past 20 days. The phenobarbital serum concentration just before the morning dose on Day 21 (i.e., at the trough of the 40 th and just prior to the 41 st dose) was reported to be 27 mg/l. Calculate the phenobarbital concentration you would have predicted on that day if E.S. has average pharmacokinetic parameters for phenobarbital. (6 pts.) A mg/l B mg/l C mg/l D mg/l E mg/l Key: A CL 0.008L / h / kg weight 0.008L / h / kg 25kg 0.2L / h 4.8L / day Vd 0.7L / kg weight 0.7L / kg 25kg 17. 5L k e CL 0.011h 0.27days Vd 17.5L 0.2L / h 1 1 Dose F S 50mg 1 1 Vd k τ L 2.9mg / L Cp e min e e ke τ ( 1 e ) ( 1 e ) 20.5mg / L Final
19 17. S.K., a 42-year-old, 54 kg woman, received a renal transplant 1.5. years ago. Following transplantation, her serum creatinine stabilized in the range of mg /dl. She has been receiving cyclosporine orally, 125mg BID over the past six months. Cyclosporine concentrations have been µg/l (whole blood HPLC assay). Her last clinic appointment was four weeks ago. Other immunosuppressive medications included prednisone 25 mg/day, azathioprine 50 mg HS. She returned to clinic yesterday complaining of increasing fatigue since her last clinic appointment. Blood and urine cultures were taken and she was admitted to the hospital with a serum creatinine of 3.1 mg/dl. Her clearance was 21.4 L/h. How would you adjust S.K. s cyclosporine dose in order to increase the cyclosporine concentration to approximately 250 µg/l? (6 pts.) A. 500 mg q12h B. 190 mg q12h C. 115 mg q12h D. 115 mg q8h E. 380 mg q12h Key: E or B Vd 4.5L / kg weight 4.5L / kg 54kg 243L CL 21.4L / h 1 k e 0.088h Vd 243L ke τ Cp Vd e µg L L e Dose ss,min / ke τ F S e e ( ) ( ) 39609µg µg mg mg q12h E Dose Cpss, ave CL τ F S 250µg / L 21.4L / h 12h µg µg 214mg 190mg q12h B Final
20 18. K.E., a 42-year-old, 62 kg female with a serum creatinine of 1.2 mg/dl, is to receive 12 gm IV methotrexate infused over four hours. Calculate the methotrexate concentration 12 hours after the end of the infusion. (8 pts.) A µm B µm C µm D µm E µm Key: C ( 140 age) weight ( ) 62 CL Cr 59.6mL / min 3.6L / h 85 SeCr CL 1.6 CLCr L / h 5.76L / h Dose Cp(12h) CL T k 12000mg e T ke t ( 1 e ) e ( 1 e ) e 520.8mg / L L / h 4h 19.7mg / L Cp( mg / L) 19.7mg / L Cp( 12h) µm 43. 4µM Final
PHA 5128 Spring 2009 First Exam (Version B)
Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide
More informationPHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationThus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.
PHA 5128 Dose Optimization II, Spring 2012, Case Study V Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More information. Although there is a little
PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance
More informationPHA Case Studies V (Answers)
PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day,
More informationPHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007 1. L.J., a 30 year old male, was diagnosed congestive heart failure (CHF). He is 5'9" tall and weights 80 kg. He was given Furosemide
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationCLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More informationTDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.
TDM Lecture 7 5 th Stage TDM of Digoxin Digoxin uses and elimination Uses: Digoxin is usually used in heart failure associated and atrial fibrillation. Elimination: About 75% of digoxin clearance occurred
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationCase Study 2 Answers Spring 2006
Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationPHA First Exam Fall 2003
PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationPHA First Exam. Fall 2004
PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem
More informationBassett Healthcare Clinical Laboratory
Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.
More informationOMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines
OMCJH.CHEM.COLL.INF.1001 Copy of version 1.0 (approved and current) Last Approval or Periodic Review Completed 10/5/2017 Next Periodic Review Needed On or Before 10/5/2019 Effective Date 10/5/2017 Controlled
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More informationA Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients
CMU. J. Nat. Sci. (2012) Vol. 11(1) 77 A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients Yupaporn Preechagoon 1 and Peeraya Somsaard 2* 1 Department
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationLearning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD
Learning Outcomes CPPD #7 Clinical Pharmacokine2cs: Concepts and Prac2ce Applica2ons Ahmed Nader, Ph.D, BCPS Ahmed Awaisu, Ph.D, B.Pharm Upon comple;on of this session, audience are expected to be able
More information2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L.
2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L. Smith, Pharm.D., BCPS Ferris State University Conflict of Interest
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationPHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq
PHARMONITOR II Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling Pierre Wallemacq NATIONAL SYMPOSIUM 20 years EEQ Leuven, March 26th 2009 1 Why monitoring of aminoglycosides?
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationDIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.
DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE Jules B. Puschett, M.D. Diuretic Resistance A clinical circumstance in which patients do not respond to a combination of salt restriction and even large
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationPharmacokinetic parameters: Halflife
Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More information4WS Neurology. Table of Contents
4WS Neurology Table of Contents 1. Phenytoin Preparations... Page 2 Monitoring... Page 2 Therapeutic Range... Page 2 Loading Doses... Page 2 Maintenance Doses... Page 3 Sampling Times... Page 3 Dose Adjustment...
More informationTarget Concentration Intervention
1 Target Concentration Intervention Dose Individualization using Monitoring of Patient Response Nick Holford University of Auckland 2 Objectives 1) Appreciate how a target concentration (TC) strategy is
More informationMyrna Y. Munar, Pharm.D., BCPS
Phenytoin PK Myrna Y. Munar, Pharm.D., BCPS Associate Professor Clickers Turn clicker on by pressing down menu button Enter you OSU student ID number The up/down diagonal arrows button on the left is the
More informationPharmacokinetics Applied to the Treatment of Asthma
Pharmacokinetics Applied to the Treatment of Asthma 2016 edition by David C. McMillan, PhD Department of Pharmacology and Experimental Neuroscience College of Medicine University of Nebraska Medical Center
More informationADME Review. Dr. Joe Ritter Associate Professor of Pharmacology
ADME Review Dr. Joe Ritter Associate Professor of Pharmacology 828-1022 jkritter@vcu.edu What percent of a weak base (pka = 7.5) and weak acid (pka = 3.5) will be respectively ionized in urine of ph 5.5?
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationTDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:
Lecture 9: Very important supplements TDM Effect of hepatic disease on drugs monitoring: Generally, hepatic clearance is determined by three main factors: - Liver blood flow (LBF). - Intrinsic capacity
More informationCAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.
CAT Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators Apr. Glynis Frans Supervisor: Prof. Apr. Katrien Lagrou 1. What are the current guidelines and recommendations on TDM for
More informationOutline. How should we do TDM? Does the evidence support TDM outcomes
Overcoming Barriers to TDM: Information and the TDM Renaissance How to integrate PK intelligence with routine clinical data Alexander A. Vinks, PharmD, PhD, FCP Professor, Director Pediatric Pharmacology
More informationDrug Disposition in Obesity & Protein-Calorie Malnutrition
Drug Disposition in Obesity & Protein-Calorie Malnutrition JBoullata, PharmD, RPh, BCNSP Associate Professor of Pharmacology & Therapeutics -and- Pharmacy Specialist in Nutrition Support University of
More informationUSES OF PHARMACOKINETICS
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center
More informationUnderstand the physiological determinants of extent and rate of absorption
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of extent and rate of absorption
More informationRational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell
1 Rational Dose Prediction Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Pharmacology Pharmacology is derived from a Greek word (pharmakon). The Greeks used
More informationA REVIEW ON DOSAGE REGIMEN
79 P a g e e-issn: 2248-9126 Vol3 Issue 2 2013 79-89. Print ISSN: 2248-9118 Indian Journal of Pharmaceutical Science & Research www.ijpsrjournal.com A REVIEW ON DOSAGE REGIMEN Ankith Kumar Reddy B*, Subhashis
More informationBasics of TDM with example drugs
Basics of TDM with example drugs Pharmacokinetic differences in drug handling between patients produce wide variability in serum drug concentrations, but dosage adjustments are generally only required
More informationPharmacokinetic Calculations
Pharmacokinetic Calculations Introduction. Pharmacokinetics involves the relationship between concentration of drug (and its metabolites), measured most often in plasma, drug dosage, and time. A vast majority
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationTherapeutic and Critical Drug Levels
6 Results Reporting As a convenience for our clients and their patients, result reports are printed daily at your facility by means of remote printer/fax machine via internet platforms (4Medica, EMR, ecare/mdoffice)
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationClinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin
Clinical Pharmacokinetics Therapeutic Drug Monitoring of Phenytoin Dr. Maysa Suyagh School of Pharmacy University of Jordan Phenytoin primarily used as an anticonvulsant and has been used in the treatment
More informationCLINICAL PHARMACOKINETICS SERVICE & ANTICOAGULATION GUIDELINES
CLINICAL PHARMACOKINETICS SERVICE & ANTICOAGULATION GUIDELINES Pharmacy Services University of Kentucky HealthCare July 2008 (30 th Edition) Editors: Daniel A. Lewis, Pharm.D., BCPS Clinical Pharmacist
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationM O N T H E R A P E D R O R I N G. Dr Tom Hartley UTAS HLS 2014
T H E R A P E U T I C D R U G M O N I T O R I N G Dr Tom Hartley UTAS HLS 2014 TOPICS 1) Why we do TDM 2) What drugs do we monitor 3) How our data assists Clinical Pharmacists & Doctors 4) Bioavailability
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationEffects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program
Effects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program `Office of Clinical Research Training and Medical Education National
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Non linear pharmacokinetics: In some cases, the kinetics of a pharmacokinetic process change from predominantly first order to predominantly zero order with increasing dose or
More informationPHAR 7632 Chapter 16
PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes
More informationContinuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More informationThe most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension
Arrhythmias in the critically ill ICU patients: Approach for rapid recognition & management Objectives Be able to identify and manage: Atrial fibrillation with a rapid ventricular response Atrial flutter
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationAUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman
AUGMENTED RENAL CLEARANCE and its clinical implications Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Introduction Recommended dosages
More informationAdult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More information